Remove 2022 Remove Food and Drug Administration Remove Patients Remove Prescription
article thumbnail

FDA extends review of GSK’s myelofibrosis drug

Pharmaceutical Technology

UK-based pharmaceutical giant GSK has announced that the US Food and Drug Administration (FDA) has extended the review period of its new drug application (NDA) for the rare bone cancer drug momelotinib by three months. In July 2022, GSK acquired the therapy as part of its $1.9bn acquisition of Sierra Oncology.

article thumbnail

Appili Therapeutics receives US patent for ATI-1501

Pharmaceutical Technology

18/072,154, filed on 30 November 2022. The tablet form of metronidazole has been the only approved oral form of the drug available on the US market. ATI-1501 has been designed to enable the wider use of metronidazole in patients who have difficulty swallowing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA pushes Daiichi Sankyo’s quizartinib approval date by three months

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has pushed quizartinib’s Prescription Drug User Fee Act (PDUFA) date in newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) for the review of updates of Risk Evaluation and Mitigation Strategies (REMS) included in the application. months , compared to 15.1

article thumbnail

Alvotech receives CRL from FDA for AVT02 BLA

Pharmaceutical Technology

Alvotech has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its biologics licence application (BLA) for AVT02, a biosimilar to Humira (adalimumab). The FDA performed an inspection of the Reykjavik site in March 2022 and found deficiencies there.

article thumbnail

FDA greenlights first OTC topical gel for erectile dysfunction

Pharmaceutical Technology

Patients with erectile dysfunction (ED) will now be able to access a topical treatment without the need for a prescription after the US Food and Drug Administration (FDA) greenlit Futura Medical’s Eroxon. ED affects approximately 18% of men in the US.

article thumbnail

Could digital therapeutics provide a solution against opioid abuse?

pharmaphorum

The struggle to manage pain for individuals has been one that goes back a long way in history, with one of the earliest recorded medical prescriptions being for opium. Another key way DTx can improve chronic pain is by helping patients to manage lifestyle factors that have the potential to exacerbate chronic pain diseases.

article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.

Pharma 103